| 000 | 00918 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517135055.0 | ||
| 264 | 0 | _c20180314 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(17)30053-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSeror, Raphaèle | |
| 245 | 0 | 0 |
_aCost-effectiveness of rituximab strategies in rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bLancet (London, England) _c01 2017 |
||
| 300 |
_a365-366 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAntirheumatic Agents |
| 650 | 0 | 4 | _aArthritis, Rheumatoid |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aRituximab |
| 700 | 1 | _aMariette, Xavier | |
| 773 | 0 |
_tLancet (London, England) _gvol. 389 _gno. 10067 _gp. 365-366 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(17)30053-3 _zAvailable from publisher's website |
| 999 |
_c26831835 _d26831835 |
||